Tech Company Financing Transactions
CellCentric Funding Round
CellCentric closed a $220 million Series D funding round on 5/6/2026. Investors included Venrock Healthcare Capital Partners and private investors.
Transaction Overview
Company Name
Announced On
5/6/2026
Transaction Type
Venture Equity
Amount
$220,000,000
Round
Series D
Investors
Venrock Healthcare Capital Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the advancement of inobrodib through pivotal clinical development studies, including continued enrollment of its recently initiated Phase 2 DOMMINO-1 study in the UK and US and initiation of the global Phase 3 DOMMINO-2 trial in the second half of 2026.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Neue Strasse 95 Industriepark Nabern
Kirchheim, 73230
DE
Kirchheim, 73230
DE
Phone
Undisclosed
Website
Email Address
Overview
CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat multiple specific cancer types. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthias Jurytko
Chief Financial Officer
Niklas Ekström
Browse more venture capital transactions:
Prev: 5/6/2026: OpenTrade venture capital transaction
Next: 5/6/2026: Modicus Prime venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs